Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavenclad in highly active relapsing multiple sclerosis (CLARIFY MS)
NCT03369665Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2018
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 4 trial of cladribine in multiple sclerosis (MS), sponsored by Merck KGaA. Started Jun 2018; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03369665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369665.